Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant

Exclusion Criteria

• •Age \< 18 years old
• •Unwilling/able to sign informed consent
• •Cleared HCV infection (and therefore not at risk for recurrent HCV)
• •Human immunodeficiency virus (HIV) co-infection
• •Hepatitis B (HBV) co-infection
• •Participation in another interventional clinical trial
• •Females of childbearing (reproductive) potential must have a negative serum pregnancy test at Screening and agree to use an acceptable method of contraception throughout their participation in the study
• •Subjects with history of hypersensitivity to rifaximin, rifampin, rifamycin antimicrobial agents, or any of the components of rifaximin
• •Subjects with history of tuberculosis infection or has received treatment for tuberculosis infection. If subject has previous positive test for tuberculosis antigen then they must have current negative chest x-ray to be eligible
• •Subject has diarrhea and positive Clostridium difficile (C. difficile) toxin via stool examination during Screening period. NOTE: Stool examination for C. difficile toxin will be performed on subjects who have diarrhea during the screening period. Results of stool tests should be confirmed as negative prior to randomization